Nose drops of pneumonia bacteria could pave way for better vaccines

NCT ID NCT05535868

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study investigates how a specific strain of pneumococcus bacteria (serotype 3) colonizes the nose of healthy adults. Researchers will give volunteers nose drops containing the bacteria to see what dose leads to colonization and how long the bacteria stay before the immune system clears them. The goal is to develop a reliable model for testing future vaccines against pneumococcal infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Serotype 3 pneumococcal bacteria (nose drops)

What this could lead to

If successful, this model could help researchers test new vaccines that prevent pneumococcal infections more effectively.

What could go wrong

This is an early-stage model study, not a treatment trial. It may not translate into real-world vaccine success, and some participants may experience temporary nasal colonization.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTROLLED HUMAN INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumonia streptococcal pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Liverpool School of Tropical Medicine

    Liverpool, L7 8XZ, United Kingdom